No Data
No Data
JenaValve, a partner of Perk Jia Medical, has been fully acquired by Edwards Lifesciences, marking a new chapter in the treatment of aortic valve regurgitation through catheterization.
Suzhou, July 26, 2024 / PRNewswire / -- On July 24, 2024, Peijia Medical (9996.HK) partner JenaValve Technology, Inc. (hereinafter referred to as JenaValve) announced an agreement with the US medical equipment giant Edwards Lifesciences (NYSE: EW, hereinafter referred to as "Edwards") for Edwards Lifesciences to acquire JenaValve wholly. After the transaction, Peijia Medical will continue to exclusively hold the JenaValve Trilogy THV system in the Greater China region.
Peijia Medical-B (09996.HK): Edwards Lifesciences plans to acquire JenaValve through a merger.
On July 26th, Guolong News reported that Peijia Medical-B (09996.HK) announced that its wholly-owned subsidiary, Marvel Finder Limited, holds about 1.91% (calculated on a fully diluted and conversion basis) of JenaValve's minority equity, which is recorded in the company's comprehensive financial statements as a financial asset measured at fair value. JenaValve has notified the company that on July 23, 2024 (US time), Edwards Lifesciences (through its wholly-owned subsidiary) agreed to acquire the shares.
Express News | Peijia Medical Sees Pre-Tax Disposal Gain of US$5.1 Mln for FY in Which Merger Closes
Express News | Peijia Medical - Merger Agreement Provides for an Upfront Payment at Closing of US$500 Mln
Express News | Peijia Medical - Edwards Lifesciences Agreed to Acquire Jenavalve Technology
Express News | Peijia Medical - Disposal of Equity Interests in Overseas Minority Investment of Co
No Data